rewirebio.iobenchmarks
Configuration

FRASER (Silverstein et al. 2026)

Configuration of FRASER: DROP v1.2.2; One versus all by tissue cohort (muscle n=71, fibroblast n=37, CHX fibroblast n=79); default parameters; FDR 5%; stranded and unstranded libraries combined.

1 evaluation · 9 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Evaluations and results

1 evaluation · 9 results. Different protocols are not a single leaderboard.

Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools) · Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)

Sorted by Accuracy (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9)) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationAccuracy (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))F1 (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))False negatives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))False positives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))MCC (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))Precision (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))Recall (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))True negatives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))True positives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
FRASER (Silverstein et al. 2026)Evaluation0.2360.3824721-0.5880.50.309021
All 9 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
0.236 Accuracy (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell F4, row 'FRASER', column 'Accuracy'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
0.382 F1 (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell I4, row 'FRASER', column 'F1'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
47 False negatives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
count · lower

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell C4, row 'FRASER', column 'False Negatives'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
21 False positives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
count · lower

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell E4, row 'FRASER', column 'False Positives'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
-0.588 MCC (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
unitless · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell J4, row 'FRASER', column 'MCC'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
0.5 Precision (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell G4, row 'FRASER', column 'Precision'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
0.309 Recall (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell H4, row 'FRASER', column 'Recall'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
0 True negatives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
count · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell D4, row 'FRASER', column 'True Negatives'
Configuration: FRASER (Silverstein et al. 2026)Protocol: Recovery of known pathogenic splicing events and outlier calls in true-negative samples, patient RNA-seq (Silverstein et al. Table S9, splicing tools)
Dataset: NIH neuromuscular diagnosed RNA-seq truth set (Silverstein et al. 2026)
21 True positives (positives per known event or gene, negatives per true-negative sample; aggregated across the tissue sets each tool was run on (Table S9))
count · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

FRASER on the NIH neuromuscular diagnosed RNA-seq truth set (splicing)

rna-splicing-20261011-silverstein2026-protocol-splicing

Aggregation: Not reported

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications (Silverstein et al., medRxiv 2026); Silverstein et al. 2026 Supplemental Tables S1-S10 (medRxiv media-3.xlsx) · Table S9 (sheet 'Table S9') cell B4, row 'FRASER', column 'True Positives'

Source checking is not independent reproduction. Release 2026-10-22-1b7cf027e4f6.

Use this configuration

How it works, versions and access
Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-22-1b7cf027e4f6
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-10-22-1b7cf027e4f6 · Record review: source checked

2 source records and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: rna-splicing-20261011-silverstein2026-config-fraser

areas
rna-transcriptomes
contexts
clinical_research
method types
conventional_pipeline
reported name
FRASER
foundation model eligible
false
version
DROP v1.2.2
parameters
One versus all by tissue cohort (muscle n=71, fibroblast n=37, CHX fibroblast n=79); default parameters; FDR 5%; stranded and unstranded libraries combined
access reuse
Open-source tool; run by the authors on the NIH Biowulf cluster
source locator
Methods 'One vs All Splice Tools'; Table S9 row label
provenance note
FRASER as run in the Silverstein et al. 2026 benchmark.
Related records

Suggest a correction